Media coverage

BioVista’s Artificial Intelligence Platform Boosts Drug Discovery BioVista has eight ongoing projects that involve using its technology to provide discovery, repositioning, adverse event profiling, patient stratification and other services for partners…BioVista said partnering discussions are ongoing for BVA-201 and BVA-601, but the company has not yet determined how far into preclinical and possibly clinical studies … Read More

By Catherine Shaffer, BioWorld Today Contributing Writer A research collaboration between Pfizer Inc. and Biovista Inc. will seek new indications for Pfizer drug candidates in development using a bioinformatics technology platform developed by Biovista. Terms of the agreement include identification of up to three new indications for each drug. Biovista will receive an undisclosed up-front … Read More

By Arlene Weintraub, BioWorld Insight On Nov. 9, the company formed a research collaboration with Biovista Inc…  

Biovista profiled in latest Insight Pharma report “Drug Repositioning:Extracting Added Value from Prior R&D Investments”. Drug repositioning is also known as drug repurposing, reprofiling, or retasking. In “on-target repurposing,” a drug’s known pharmacological mechanism is applied to a different therapeutic indication than that for which it was initially developed. Even more innovative is “off-target repurposing, ” … Read More

BioWorld & Medical Device Daily BioVista Inc. has drugs in various stages of research and preclinical development for eye disorders, diabetes and obesity. According to its website, the Charlottesville, Va.-based company has identified four novel targets involved in diabetes and obesity that lend them- selves to the development of RNAi drugs. Using artificial intelligence (AI), … Read More